Tag: Alzheimer’s
FDA Gives Full Approval to Alzheimer Disease Drug Leqembi
While Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds
Variation in Total Cholesterol, Triglycerides Linked to Alzheimer Disease Risk
Those in highest quintile of total cholesterol, triglycerides had increased risk for AD and Alzheimer-related dementias
Intranasal Insulin May Have Pro-Cognitive Benefits
Improvement in global cognition seen for patients with Alzheimer disease/MCI, but no effects seen for healthy individuals, other patient populations
Instrumental Activities of Daily Living Test Could ID Alzheimer Disease
Association found between simulated real-life IADL and interactions of amyloid and early tau accumulation in cognitively normal seniors
Gut Microbial Taxonomic Profiles Differ With, Without Preclinical Alzheimer Disease
Change in gut microbiome composition associated with β-amyloid and tau pathological brain biomarkers
Bladder Cancer Treatment May Lower Risk for Alzheimer and Related Dementias
Greater effect seen for patients aged 70 years and older at time of bacillus Calmette-Guerin vaccination
Medicare Will Cover New Class of Alzheimer Drugs if Fully Approved by FDA, With...
Drug makers will also have to gather and keep data in a registry showing how the drugs are working in the real world
Causal Link ID’d for Alzheimer Disease, Generalized Epilepsy
Genetic predisposition to Alzheimer's also linked to increased risk of focal epilepsy with hippocampal sclerosis
Allopurinol May Cut Risk for Neurodegenerative Diseases
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Medicare Spending Would Increase $2.0 to $5.1 Billion With Lecanemab
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
